CN118019526A - 用于制备将有效负载分子递送至气道上皮的脂质纳米颗粒组合物的方法 - Google Patents
用于制备将有效负载分子递送至气道上皮的脂质纳米颗粒组合物的方法 Download PDFInfo
- Publication number
- CN118019526A CN118019526A CN202280065046.4A CN202280065046A CN118019526A CN 118019526 A CN118019526 A CN 118019526A CN 202280065046 A CN202280065046 A CN 202280065046A CN 118019526 A CN118019526 A CN 118019526A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- lipid
- buffer
- composition
- lipid nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225822P | 2021-07-26 | 2021-07-26 | |
| US63/225822 | 2021-07-26 | ||
| PCT/US2022/038152 WO2023009422A1 (en) | 2021-07-26 | 2022-07-25 | Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118019526A true CN118019526A (zh) | 2024-05-10 |
Family
ID=82899171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280065046.4A Pending CN118019526A (zh) | 2021-07-26 | 2022-07-25 | 用于制备将有效负载分子递送至气道上皮的脂质纳米颗粒组合物的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240366522A1 (https=) |
| EP (1) | EP4376815A1 (https=) |
| JP (1) | JP2024527940A (https=) |
| CN (1) | CN118019526A (https=) |
| TW (1) | TW202320737A (https=) |
| WO (1) | WO2023009422A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120718086A (zh) * | 2024-06-13 | 2025-09-30 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN118829423A (zh) * | 2021-11-12 | 2024-10-22 | 摩登纳特斯有限公司 | 用于将有效载荷分子递送至气道上皮的组合物 |
| CN121487722A (zh) * | 2023-04-14 | 2026-02-06 | 北京剂泰生命科技有限公司 | 靶向脾的脂质纳米颗粒 |
| WO2025111297A1 (en) | 2023-11-21 | 2025-05-30 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| AU2017357758B2 (en) * | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| US20210137840A1 (en) * | 2018-04-25 | 2021-05-13 | Ethris Gmbh | Lipid-based formulations for the delivery of rna |
| JP7488193B2 (ja) * | 2018-05-24 | 2024-05-21 | トランスレイト バイオ, インコーポレイテッド | チオエステルカチオン性脂質 |
| CN118697900A (zh) * | 2019-01-31 | 2024-09-27 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US20230181483A1 (en) * | 2019-07-08 | 2023-06-15 | Translate Bio, Inc. | Improved mrna-loaded lipid nanoparticles and processes of making the same |
-
2022
- 2022-07-25 WO PCT/US2022/038152 patent/WO2023009422A1/en not_active Ceased
- 2022-07-25 CN CN202280065046.4A patent/CN118019526A/zh active Pending
- 2022-07-25 JP JP2024504834A patent/JP2024527940A/ja active Pending
- 2022-07-25 TW TW111127850A patent/TW202320737A/zh unknown
- 2022-07-25 US US18/291,710 patent/US20240366522A1/en active Pending
- 2022-07-25 EP EP22754669.4A patent/EP4376815A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120718086A (zh) * | 2024-06-13 | 2025-09-30 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240366522A1 (en) | 2024-11-07 |
| JP2024527940A (ja) | 2024-07-26 |
| WO2023009422A1 (en) | 2023-02-02 |
| TW202320737A (zh) | 2023-06-01 |
| EP4376815A1 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118019526A (zh) | 用于制备将有效负载分子递送至气道上皮的脂质纳米颗粒组合物的方法 | |
| US12144895B2 (en) | Stabilized formulations of lipid nanoparticles | |
| US20230285310A1 (en) | Compositions for the delivery of payload molecules to airway epithelium | |
| US20250281418A1 (en) | Lipid nanoparticle formulations and methods of synthesis thereof | |
| EP3852728B1 (en) | Preparation of lipid nanoparticles and methods of administration thereof | |
| US20240335393A1 (en) | Processes for preparing lipid nanoparticle compositions | |
| US20250017867A1 (en) | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease | |
| AU2021377895A9 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | |
| US20250049727A1 (en) | Compositions for the delivery of payload molecules to airway epithelium | |
| WO2024197310A1 (en) | Peg targeting compounds for delivery of therapeutics | |
| WO2024197309A1 (en) | Peg targeting compounds for delivery of therapeutics | |
| US20260035707A1 (en) | Engineered polynucleotides for temporal control of expression | |
| WO2024197307A1 (en) | Peg targeting compounds for delivery of therapeutics | |
| EP4704816A1 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |